340B Rebates: Who Bears the Cost of Changing How the Program Works?

Why the 340B Program Matters

Congress established the 340B Drug Pricing Program in 1992 to help eligible healthcare organizations stretch scarce resources and serve patients. Under the program, manufacturers participating in Medicaid and Medicare Part B agree to provide qualifying outpatient drugs at or below a statutory ceiling price to eligible hospitals, health centers and other providers known as covered entities. The program has generally delivered that price through an upfront purchasing discount. [1]

That purchasing arrangement is now embedded in many organizations’ pharmacy operations. Covered entities use 340B savings in different ways, which can include supporting medication access, specialty services and care for patients who may face barriers to treatment. The program is also operationally complex: hospitals and clinics may use in-house or contract pharmacies, wholesalers, inventory replenishment systems and third-party administrators to determine which transactions qualify.

The 340B statute prohibits diversion of discounted drugs to ineligible patients and duplicate discounts involving Medicaid rebates. Determining which transactions qualify and identifying overlapping price concessions have become persistent administrative questions as the program and pharmaceutical distribution arrangements have grown. [1]

HRSA’s revised rebate pilot is designed to test whether a rebate-based approach addresses these administrative questions more effectively than the existing upfront-discount model. It applies to a limited set of drugs, rather than changing 340B purchasing across the program. [1, pp. 48,894–48,896]

Why Manufacturers Are Interested in a Rebate Model

Manufacturers have argued that an upfront discount can make it difficult to verify the specific transaction that ultimately qualifies for 340B pricing. They have sought greater visibility into claims data to identify duplicate discounts, evaluate eligibility and reconcile overlapping requirements across federal drug-pricing programs. For selected Medicare-negotiated drugs, the pilot also addresses potential overlap between 340B discounts and Medicare Maximum Fair Price (MFP) discounts; these price concessions are not cumulative. [1, pp. 48,884–48,886]

Supporters of rebate-based arrangements contend that linking payment to a validated dispensing or administration record could improve claims-level transparency and reduce the need to identify problems only through retrospective audits. They also argue that covered entities and their administrators already collect much of the information that would be used for reporting. [1]

Those arguments do not resolve every implementation issue. More transaction data raises questions about the information manufacturers may receive, permitted uses of that information, privacy, platform governance and the cost of producing and verifying claims. Whether the anticipated benefits materialize is part of what the pilot is designed to examine.

What the Revised Pilot Would Actually Change

In July 2026, the Health Resources and Services Administration announced a revised, voluntary pathway for qualifying manufacturers to provide 340B pricing through rebates instead of upfront discounts. The pilot is limited to selected drugs in the Medicare Drug Price Negotiation Program with initial price applicability years 2026 and 2027, during their applicable pricing periods. HRSA estimates that the included products represent less than 5.5% of total 340B sales, based on 2025 data. The rest of the program would continue using upfront discounts in 2027. [1, pp. 48,893–48,894; 2]

For an approved participating product, the covered entity would order through existing distribution channels at wholesale acquisition cost (WAC). Following an eligible dispense or administration, it would submit specified transaction information. The rebate would equal WAC minus the applicable 340B ceiling price on the day of dispense and would be paid at the unit level. This means the financial benefit arrives through a separate transaction rather than being reflected in the initial acquisition price. [1]

The revised framework includes several operational safeguards. Manufacturers must fund the required submission platforms and provide technical assistance. Their approved plans must allow at least 90 calendar days’ notice before implementation, and covered entities must have at least 45 calendar days after dispensing to submit data, with specified allowances for exceptions. Manufacturers must pay the rebate or issue a documented denial within ten calendar days after receiving a complete submission. An incomplete submission can restart that payment clock when the missing information is supplied. [1]

The pilot is scheduled to begin January 1, 2027, for manufacturers whose rebate plans receive HHS approval. It does not change purchasing for products outside its limited scope. [1]

Why Hospitals Are Concerned

Hospitals and health systems have raised concerns about the effect of moving from a known upfront acquisition discount to a later rebate. One issue is liquidity: an organization may need to purchase a high-cost drug at WAC, hold it in inventory, dispense or administer it, submit transaction information and wait for a validated rebate. Even a ten-day payment requirement begins after a complete submission, not necessarily on the purchase date. [1]

Covered entities have also pointed to potential administrative costs, including staff training, system changes, reconciliation, disputed transactions and changes to wholesaler credit arrangements. Their concern is not limited to whether a rebate ultimately arrives. For some hospitals, uncertainty or new financing costs could affect resources used to maintain services, including medication access and other programs serving vulnerable patients. Those effects would differ by facility and cannot be inferred from a uniform estimate. [1]

HRSA takes a different view of the likely financial impact. It expects the ten-day deadline, unit-level rebates and existing wholesaler payment windows to allow many organizations to receive rebates before their wholesaler invoices become payable. The agency also expects existing pharmacy systems and third-party administrators to absorb much of the additional work, although it acknowledges that some covered entities may need new resources. [1]

The two positions turn in part on actual purchasing arrangements. A rebate paid before the relevant wholesaler invoice is due may create little additional financing expense. A different experience is possible when inventory moves slowly, submissions are incomplete, credit terms are tight or reconciliation is difficult. The pilot’s practical effects will need to be assessed across different provider types and purchasing models.

Who Bears the Financial and Administrative Costs?

The answer is not a single stakeholder. The revised pilot assigns some obligations explicitly, while other costs depend on how organizations purchase drugs, operate their systems and contract with service providers.

Participant

Responsibility or potential exposure

Manufacturers

Fund the required data-submission platforms; validate eligible submissions; pay or document denials on time; provide technical assistance and required reporting.

Covered entities

Manage purchasing and eligible-claim submissions; reconcile rebates; potentially absorb internal system, training, staffing and working-capital costs.

Third-party administrators and technology vendors

Perform data extraction, submission, monitoring and reconciliation under their contracts; compensation and liability for additional services depend on those agreements.

Wholesalers

Existing invoice, credit and payment terms influence whether the covered entity receives its rebate before the acquisition invoice is due.

HRSA estimates an average annual claims-reporting cost of approximately $34,320 per covered entity under its information-collection analysis, with actual costs varying by entity type. This is an average regulatory estimate, not a prediction of what any particular hospital will spend. Manufacturers are required to fund the submission platforms, but that does not necessarily cover all costs of a covered entity’s internal preparation, integration, monitoring or dispute management. [1, pp. 48,892–48,894]

The contractual questions follow naturally. Who corrects an incomplete claim? Who tracks the restarted payment deadline? Which party carries the cost of an error, additional integration work or a reconciliation backlog? Existing arrangements may address some of these questions, but organizations should not assume every agreement was written for a rebate workflow.

Contract Pharmacy Considerations

Contract pharmacy arrangements add another operational layer. A covered entity may rely on a retail or specialty pharmacy partner to dispense eligible drugs and on an administrator to determine eligibility and manage replenishment. The covered entity retains responsibility for 340B compliance, even when other organizations perform parts of the workflow. HRSA’s notice includes contract pharmacy arrangements in its discussion of the pilot and acknowledges the complexity of coordinating claims and transaction data across these relationships. [1, pp. 48,887–48,888, 48,893–48,894]

Depending on the arrangement, the parties may need to clarify who gathers and submits transaction data, corrects incomplete submissions, tracks rebate payments and resolves discrepancies. Existing contract pharmacy and administrator agreements should be reviewed for data-sharing permissions, confidentiality, reconciliation duties, payment allocation and dispute procedures. The extent of any changes will depend on how the covered entity already operates and the terms of its contracts.

Data, Denials and the Limits of Verification

The revised pilot requires defined data elements, appropriate safeguards for personal and health information, reconciliation reporting and documented reasons for rebate denials. Under the notice, manufacturers may not deny a rebate based on covered-entity eligibility concerns, diversion, Medicaid duplicate-discount concerns or perceived insufficient WAC purchases. Those issues must instead be raised with HRSA or pursued through the program’s established audit and dispute mechanisms. The notice permits certain documented denials, including when a rebate would duplicate an applicable Medicare Maximum Fair Price discount or when another covered entity has already received a 340B rebate on the same claim. Because the pilot concerns selected Medicare-negotiated drugs during their price applicability periods, MFP nonduplication is part of the pilot’s design. [1, p. 48,903]

These provisions limit the grounds for denial without eliminating the need for claim validation and dispute management. Covered entities and their service providers should establish who reviews rejected submissions, corrects incomplete data, preserves records, monitors payment deadlines and escalates recurring problems. Relevant contracts should address data use, privacy, audit rights, service standards and responsibility for errors.

The Legal and Medicare Payment Context

The revised pilot follows an earlier program scheduled to begin in January 2026. On December 29, 2025, a federal district court preliminarily enjoined the earlier program, finding that HRSA had likely failed to adequately consider hospitals’ reliance on upfront discounts. HRSA subsequently withdrew that program. On February 10, 2026, the district court granted the parties’ joint motion for vacatur and remand, vacating the earlier notices and manufacturer approvals. Neither order was a final ruling on the lawfulness of rebate mechanisms generally; the revised 2026 pilot is a distinct agency action. [3, 4]

In a separate dispute, the D.C. Circuit held in July 2026 that Section 340B permits rebate mechanisms when the Secretary of Health and Human Services affirmatively provides for them, but manufacturers may not impose such models unilaterally without Secretarial approval. The court did not decide whether any particular proposed arrangement should receive approval or resolve possible procedural challenges to the revised pilot. [5]

A separate proposal could also affect hospital financial planning in 2027. In its CY 2027 Hospital Outpatient Prospective Payment System proposed rule, CMS proposed paying most separately payable 340B-acquired drugs at average sales price minus 33.4%, rather than the generally applicable ASP plus 6% rate. CMS estimated lower Medicare drug and beneficiary payments, with a corresponding budget-neutral increase in other outpatient payments. As of September 2026, this remains a proposal, not a finalized payment change or an additional requirement of the HRSA rebate pilot. Financial effects would vary across hospitals. [6]

Hospitals evaluating the pilot may therefore want to model the acquisition and rebate process separately from potential Medicare payment changes, then consider their combined impact if both policies ultimately take effect.

Five Questions Organizations Should Ask

Financial exposure: For affected drugs, when do we purchase, dispense, submit claims, receive rebates and pay our wholesalers?

Operational readiness: Can existing pharmacy, claims and accounting systems support the required reporting and reconciliation processes?

Contracting: Do vendor and administrator agreements clearly assign responsibility for errors, incomplete submissions, payment tracking, disputes and additional service costs?

Data and compliance: Are approved data uses, privacy safeguards, reporting obligations and denial-review procedures clear?

Policy status: Who will track HRSA guidance, relevant litigation and the separate CMS payment proposal?

What the Pilot May Tell Us

The pilot applies to a small share of total 340B sales, but it offers a defined setting in which to measure how a claims-based rebate process works. Relevant evidence will include actual payment timing, administrative expense, rejection and dispute rates, platform performance and the differences among covered entities with distinct purchasing and technology arrangements. A broader shift is not predetermined by this limited pilot.

The practical question is whether participating organizations can deliver the required data, obtain accurate and timely rebates, allocate operational responsibilities and understand the costs they incur. Those results, rather than assumptions about how either model should perform, will provide a more useful basis for evaluating the program.

How Lanton, Lanton & Sosa Law Can Help

Lanton, Lanton & Sosa Law advises healthcare and life sciences organizations on pharmaceutical reimbursement, regulatory compliance, commercial contracting and pharmacy operations. As 340B requirements evolve, we help clients evaluate the rules affecting their businesses, review agreements and address implementation and compliance questions.

Organizations reviewing new rebate arrangements, technology or administrator contracts, or changes to purchasing and reimbursement can contact the firm to discuss their specific circumstances: www.lantonlaw.com/contact.

This publication is provided for general informational purposes only and does not constitute legal advice. Regulatory guidance, litigation and Medicare payment policies may change.

Selected Sources

[1] Health Resources and Services Administration, Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. 48,883–48,903 (Aug. 3, 2026), especially 48,884–48,886 (statutory framework and MFP), 48,892–48,894 (cost analysis and pilot scope), and 48,902–48,903 (plan requirements and denials). https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15633.pdf

[2] HRSA, Revised 340B Rebate Model Pilot Program announcement (July 31, 2026). https://www.hrsa.gov/about/news/press-releases/revised-340b-program-2026

[3] American Hospital Association v. Kennedy, 820 F. Supp. 3d 30, 44 (D. Me. 2025) (preliminary injunction concerning the earlier pilot, Dec. 29, 2025). https://docs.justia.com/cases/federal/district-courts/maine/medce/2%3A2025cv00600/69459/90

[4] American Hospital Association v. Kennedy, Order Granting Joint Motion for Vacatur and Remand (D. Me. Feb. 10, 2026). https://docs.justia.com/cases/federal/district-courts/maine/medce/2%3A2025cv00600/69459/115

[5] Novartis Pharmaceuticals Corp. v. Kennedy, No. 25-5177 (D.C. Cir. July 21, 2026) (approval required before manufacturers may implement rebate arrangements unilaterally). https://law.justia.com/cases/federal/appellate-courts/cadc/25-5177/25-5177-2026-07-21.html

[6] CMS, CY 2027 Hospital Outpatient Prospective Payment System Proposed Rule Fact Sheet (July 2, 2026). https://www.cms.gov/newsroom/fact-sheets/calendar-year-2027-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center